Loading clinical trials...
Loading clinical trials...
Analysis of E4494 Tissues to Determine the Prognostic Significance of Biomarkers in Diffuse Large B Cell Lymphoma (DLBCL) Treated With Standard Chemotherapy (CHOP) Plus Rituximab ®)1
Conditions
Interventions
laboratory biomarker analysis
Start Date
September 24, 2007
Primary Completion Date
September 24, 2008
Completion Date
September 24, 2008
Last Updated
May 19, 2017
NCT05529069
NCT07388563
NCT06337318
NCT05139017
NCT06263491
NCT06189391
Lead Sponsor
ECOG-ACRIN Cancer Research Group
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions